SGEN — Seagen Share News
0.000.00%
Last trade - 00:00HealthcareBalancedLarge Cap
- $43.15bn
- $41.92bn
- $1.96bn
Corporate bond issuance picks up after slow April
Brief: Pfizer Reaffirms Full-Year 2023 Financial Guidance
Refinitiv Newscasts - U.S. Day Ahead: Markets lack lustre as investors ready for FOMC this week
What to Watch in the Day Ahead - Tuesday, May 2
Refinitiv Newscasts - U.S. Week Ahead: All eyes on the Fed
What to Watch for the Week Ahead and on Monday, May 1
Seagen Inc reports results for the quarter ended in March - Earnings Summary
Brief: Seagen Posts Q1 Total Revenues Of $520 Million
Seagen Inc expected to post a loss of 82 cents a share - Earnings Preview
Big Pharma risks overdosing on M&A
Brief: Seagen Inc CEO 2022 Total Compensation $57.5 Mln – SEC Filing
U.S. STOCKS ON THE MOVE-AMC Entertainment, Trilogy Metals, Nogin
U.S. STOCKS ON THE MOVE-Duckhorn Portfolio, BullFrog AI, VBI Vaccines
Canaccord Genuity expects more deals with orphan drugs, biologics
FDA nod for Seagen's cancer combo therapy makes a 'multi-blockbuster' - Analysts
U.S. STOCKS ON THE MOVE-Acuity Brands, Cardlytics, Tiziana
FDA nod for Seagen's cancer combo therapy makes 'multi-blockbuster' - Analysts
Brief: FDA Grants Accelerated Approval For Padcev® (Enfortumab Vedotin-Ejfv) With Keytruda® (Pembrolizumab) For First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer
Brief: FDA Grants Accelerated Approval For Padcev With Keytruda For First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer